Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FNCH Finch Therapeutics Group	$13.48 +12.1%	$12.77	$10.15 ▼ $15.85	$21.65M	1.19	2,237 shs	15,888 shs
OTLC Oncotelic Therapeutics	$0.05 -2.0%	$0.05	$0.02 ▼ $0.07	$20.89M	-0.9	86,763 shs	153,605 shs
PMN Promis Neurosciences	$0.55 +4.6%	$0.59	$0.38 ▼ $1.59	$17.16M	-0.04	1.20 million shs	184,577 shs
ULUR ULURU		$0.00	$0.10 ▼ $0.79	$5.35M	-3.13	6,691 shs	N/A

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FNCH Finch Therapeutics Group	-3.76%	-0.99%	-2.12%	-7.46%	+8.18%
OTLC Oncotelic Therapeutics	0.00%	+2.00%	+1.80%	-17.48%	+137.21%
PMN Promis Neurosciences	-7.10%	-25.01%	-53.13%	+2.12%	-56.62%
ULUR ULURU	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OTLC Oncotelic Therapeutics	0.3643 of 5 stars	0.0	3.0	0.0	0.0	1.1	1.7	0.0
PMN Promis Neurosciences	2.8028 of 5 stars	3.5	5.0	0.0	0.0	1.4	0.8	0.6
ULUR ULURU	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FNCH Finch Therapeutics Group	0.00	N/A	N/A	N/A
OTLC Oncotelic Therapeutics	0.00	N/A	N/A	N/A
PMN Promis Neurosciences	3.00	Buy	$4.33	689.31% Upside
ULUR ULURU	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ULUR, FNCH, OTLC, and PMN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/21/2025	PMN Promis Neurosciences	Leede Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy
7/14/2025	PMN Promis Neurosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
7/14/2025	PMN Promis Neurosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	$14.25 per share	N/A
OTLC Oncotelic Therapeutics	$70K	292.52	$0.01 per share	9.93	$0.02 per share	2.50
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	($0.01) per share	N/A
ULUR ULURU	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FNCH Finch Therapeutics Group	-$74.75M	-$8.82	N/A	∞	N/A	N/A	-69.14%	-26.92%	N/A
OTLC Oncotelic Therapeutics	-$4.52M	-$0.01	N/A	∞	N/A	N/A	-9.62%	-2.72%	N/A
PMN Promis Neurosciences	$2.78M	-$0.21	N/A	N/A	N/A	N/A	-266.69%	-131.59%	N/A
ULUR ULURU	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest ULUR, FNCH, OTLC, and PMN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	PMN Promis Neurosciences	-$0.22	-$0.29	-$0.07	-$0.29	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	N/A
OTLC Oncotelic Therapeutics	N/A	N/A	N/A	N/A	N/A
PMN Promis Neurosciences	N/A	N/A	N/A	N/A	N/A
ULUR ULURU	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FNCH Finch Therapeutics Group	N/A	3.87	3.87
OTLC Oncotelic Therapeutics	N/A	0.01	0.01
PMN Promis Neurosciences	N/A	0.97	0.97
ULUR ULURU	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FNCH Finch Therapeutics Group	21.77%
OTLC Oncotelic Therapeutics	N/A
PMN Promis Neurosciences	50.13%
ULUR ULURU	N/A

Insider Ownership

Company	Insider Ownership
FNCH Finch Therapeutics Group	44.90%
OTLC Oncotelic Therapeutics	39.22%
PMN Promis Neurosciences	6.11%
ULUR ULURU	1.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FNCH Finch Therapeutics Group	190	1.61 million	885,000	No Data
OTLC Oncotelic Therapeutics	20	409.52 million	248.91 million	Not Optionable
PMN Promis Neurosciences	5	32.69 million	30.69 million	Not Optionable
ULUR ULURU	2	30.57 million	30.24 million	Not Optionable

ULUR, FNCH, OTLC, and PMN Headlines

Recent News About These Companies

Virgin Australia & Starlight Foundation Celebrate 15 Years Of Partnership In The Heart Of Australia

August 21 at 2:49 AM | bandt.com.auB

Starlight Children’s Foundation and Virgin Australia mark 15 years of granting wishes

August 20 at 9:48 PM | travelweekly.com.auT

Starlight Foundation grants ‘unique Uluru experience’ to bring joy ...

August 20 at 4:48 PM | themercury.com.auT

Starlight Foundation grants ‘unique Uluru experience’ to bring joy lil battler following tough diagnosis

August 18 at 3:51 AM | ntnews.com.auN

Douglas Crabbe, sentenced to life for Uluru mass murder, has latest parole bid rejected

August 16, 2025 | ntnews.com.auN

Uluru truck mass murderer Douglas Crabbe's parole bid rejected in WA

August 14, 2025 | msn.com

Uluru 1Q Net Y192.00M Vs Net Y48.00M

August 14, 2025 | marketwatch.com

Elder likens algal bloom devastation to watching Uluru being destroyed

August 13, 2025 | msn.com

Finding the ‘copper coloured mountain’: Why Kung Fu nuns and more are on a pilgrimage to Uluru

August 12, 2025 | townsvillebulletin.com.auT

The measure of success: How Australia can become a long-term civilisation

August 12, 2025 | abc.net.auA

Australian swim sensation Kaylee McKeown reveals romance with ex-AFL player Declan Watson

August 11, 2025 | news.com.auN

From Melbourne to Darwin: A 17-day journey through Australia’s spiritual heartland

August 6, 2025 | neoskosmos.comN

Busy tourist season at Uluru equating to stronger NITA trainee outcomes

August 6, 2025 | ntnews.com.auN

PM grilled by Uluru Statement architects for failures on Closing the Gap

August 2, 2025 | msn.com

'Enough is enough': Uluru Statement architects condemn governments for Closing the Gap failures

August 1, 2025 | sbs.com.auS

10 best national parks in Australia all outdoor lovers should visit

July 30, 2025 | lifestyleasia.comL

Rainband spreading across Australia – here's what to expect this weekend

July 25, 2025 | weatherzone.com.auW

Territory Growth Initiative targets investment and jobs

July 16, 2025 | thechronicle.com.auT

National Indigenous Training Academy recognised for its training excellence at Territory awards

July 11, 2025 | ntnews.com.auN

Virgin Australia cuts low season direct flights between Brisbane and Red Centre

July 10, 2025 | thechronicle.com.auT

New MarketBeat Followers Over Time

Media Sentiment Over Time

ULUR, FNCH, OTLC, and PMN Company Descriptions

Finch Therapeutics Group NASDAQ:FNCH

$13.48 +1.45 (+12.05%)

As of 03:58 PM Eastern

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

Oncotelic Therapeutics OTCMKTS:OTLC

$0.05 0.00 (-1.96%)

As of 03:43 PM Eastern

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies. Oncotelic Therapeutics, Inc. is based in Agoura Hills, California.

Promis Neurosciences NASDAQ:PMN

$0.55 +0.02 (+4.59%)

Closing price 04:00 PM Eastern

Extended Trading

$0.53 -0.02 (-3.10%)

As of 07:36 PM Eastern

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

ULURU OTCMKTS:ULUR

ULURU Inc., a specialty medical technology company, researches, develops, and commercializes a range of wound care and muco-adhesive film products based on its patented Nanoflex and OraDisc technologies in the United States and internationally. The company provides Altrazeal, a transforming powder dressing that is used for the treatment of various wounds, such as partial thickness burns, donor sites, and surgical and traumatic wounds, as well as chronic wounds, including diabetic foot, venous leg, and pressure ulcers. Its products also include Aphthasol paste for the treatment of canker sores; OraDisc A for canker sores; and OraDisc B, which is used for the treatment and management of oral pain. ULURU Inc. was founded in 1987 and is based in Addison, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time